Posted On: 04/08/2015 11:39:32 PM
Post# of 30066
http://www.jci.org/articles/view/71640
The results of the present study provide proof of concept with respect to the involvement of serotonergic mechanisms in the development of LIDs. Currently, no medical treatment could be designated as efficacious for LIDs and anti-LIDs treatments, and phase III trials remain an ongoing challenge for investigators. Our present data support the development and use of potent 5-HT1A agonists for the management of LIDs.
Eltoprazine (DU-28,853) is a drug of the phenylpiperazine class which is a serenic or antiaggressive agent.[1] It acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.[2] It is closely related to fluprazine and batoprazine, which are similarly acting drugs.
The results of the present study provide proof of concept with respect to the involvement of serotonergic mechanisms in the development of LIDs. Currently, no medical treatment could be designated as efficacious for LIDs and anti-LIDs treatments, and phase III trials remain an ongoing challenge for investigators. Our present data support the development and use of potent 5-HT1A agonists for the management of LIDs.
Eltoprazine (DU-28,853) is a drug of the phenylpiperazine class which is a serenic or antiaggressive agent.[1] It acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.[2] It is closely related to fluprazine and batoprazine, which are similarly acting drugs.
(0)
(0)
